We’ve brought together a collaborative and patient-focused group of physicians, scientists and seasoned business leaders.
Eboo Versi, MD PhDCEO, Chairman and Founder
Dr. Versi is the CEO and founder of DMK Pharmaceuticals. He has over 30 years of experience as a physician, surgeon, academic, teacher, entrepreneur, investor, and senior executive. He is the inventor of several patents, and owns over thirty U.S. and international patents under the Versi Group and its licensees. Dr. Versi has served as a pharmaceutical executive at several large (Pfizer, Astellas) and small (Pliva, Mt Cook) companies in a medical capacity culminating as Chief Medical Officer, and head of drug development. Dr. Versi received his Masters and Doctorate from Oxford University and Medical Degree from Cambridge University in the UK.
Neil Frazer, MDChief Medical Officer
Dr. Frazer is the Chief Medical officer, and co-founder of DMK Pharmaceuticals. He has over 30 years of experience in managing pharmaceutical product development programs. He has participated in over thirty drug and device development initiatives, leading to successful submissions to US and global regulatory authorities. He strongly believes in working with practicing clinicians, whose key aim is to help their patients achieve a better quality of life through use of existing and innovative therapies. Dr. Frazer holds a B.Sc. and MB.ChB (Medical Degree) from the University of Edinburgh Medical School, and completed Fellowships at the Royal College of Anaesthetists and Royal College of Physicians.
Bina Julian, PhDDirector of Research Operations
Dr. Bina Julian is the Director of Research Operations of DMK Pharmaceuticals. She has spent the last 15 years advancing pharmaceutical research and innovation at Pfizer, the Broad Institute of Harvard and MIT, Tufts Medical Center and Versi Group companies (DMK, Dina, Opus). Dr. Julian holds Master of Engineering and Bachelor of Science degrees in biomedical engineering from Cornell University, and a PhD in Pharmacology and Experimental Therapeutics from Tufts Graduate School of Biomedical Sciences.
Kevin Statz, MBAChief Commercial Officer
Mr. Statz has 25 years of diverse commercial biopharmaceutical experience in the specialty space, which includes new product planning and multiple product launches. He has held leadership positions at Anika, Alkermes and Collegium, building key commercial capabilities including distribution, sales operations, managed markets and trade, pricing, Payer, Physician and GPO contracting, all go-to-market strategies, and developing field sales capabilities. He has led marketing and strategy for multiple Brands, across HCP, Managed Markets & Trade, Government Affairs, LTC & Hospital. Mr. Statz holds Bachelor of Science degrees in Biology and Biochemistry from Florida State University, as well as an MBA from MIT Sloan School of Management.
Paul Jeffrey, MBAVP Business Development
Mr. Jeffrey is an experienced pharma business executive and advisor with over 40 years of pharmaceutical research, product development, marketing and business development experience. He is presently Founder and owner of PJ BioPharma Solutions, a boutique consulting firm that provides strategic and BD advisory services to biotechs and pharma companies. He also serves on several startup pharma company boards. Prior to consulting, Paul was VP Early Commercial Development at Pfizer and during his nearly 30 years with the company was responsible for the commercial development and pre-approval marketing of Pfizer's Primary Care Rx pipeline as well as commercial leader for a great number of Pfizer's licensing, co-development/marketing deals and acquisitions.
SRINIVAS NALAMACHU, MDOpioid Use Disorder Expert
Pain Management and Clinical Trial Expert
Clinical Urology Expert
Parkinson’s Disease Expert
EDWARD AHN, PHD
Business Strategy Advisor
DAVID J. MARGUGLIO
Business & Financial Strategy Advisor